Investigator and DRCI: roles, responsibilities and friction points

An indispensable partnership, often poorly calibrated

The relationship between the principal investigator and the clinical research office (DRCI, Direction de la Recherche Clinique et de l'Innovation) is at the heart of any academic clinical study. Yet it is frequently a source of misunderstandings, unanticipated delays, and mutual frustration — not for lack of goodwill, but because each party is insufficiently aware of the other's constraints and responsibilities.

Understanding what each party can and cannot do, at which point, and with which means, is an essential operational skill for any investigator who wants to bring their projects to completion within realistic timelines.

Who does what: mapping the responsibilities

The investigator's role

The principal investigator is responsible for the scientific conduct of the study. Their responsibilities cover:

• the scientific design of the project (research question, design, endpoints);
• writing the synopsis and the protocol, in conjunction with the methodologist;
• the recruitment and follow-up of participants;
• the reporting of serious adverse events (SAEs);
• the quality of the data entered in the case report form;
• the scientific integrity of the results and their publication.

The investigator is not the sponsor — unless they carry the project themselves on an individual basis, which is rare in academic practice.

The DRCI's role

The DRCI provides the institutional sponsorship of the study on behalf of the establishment. As sponsor, it is responsible for:

• the administrative and budgetary feasibility of the project;
• regulatory submissions (CPP, the research ethics committee; ANSM, the French medicines agency; CNIL, the French data protection authority);
• contractual management (inter-establishment agreements, research contracts, vendor contracts);
• the logistical management of the study;
• sponsor insurance;
• monitoring and auditing;
• data management and its regulatory archiving.

The DRCI does not validate scientific quality — it validates operational feasibility and regulatory compliance.

The CRA's role: distinct profiles

Each establishment may have a different way of operating and different job descriptions for the title of CRA (ARC, Attaché de Recherche Clinique — clinical research associate). However, to simplify, we can distinguish two functions with very different scopes, often confused by investigators early in their research career.

The investigator-side CRA (or field CRA / site CRA)

They work within the clinical department, in close collaboration with the care teams. Their role is centered on the operational conduct of the study at the patient level:

• identification and pre-screening of participants according to the inclusion and exclusion criteria;
• coordination of research visits with the patient and the care teams;
• collection, verification, and entry of data in the case report form (paper or eCRF);
• follow-up of participants and management of missed appointments or study withdrawals;
• interface with the monitor during monitoring visits (access to source documents).

The investigator-side CRA is often employed by the healthcare establishment or directly by the department. In multicenter studies, each center normally has its own field CRA.

The sponsor-side CRA (or clinical project manager)

They work within the DRCI, on behalf of the institutional sponsor. Their role is cross-cutting and centered on the overall management of the study:

• preparation and follow-up of regulatory submissions (CPP, ANSM, CNIL);
• drafting and follow-up of inter-establishment partnership agreements in multicenter studies;
• communication with the investigator-side CRAs in the different centers;
• setting up and following up the monitoring plan;
• central document management (document versions, regulatory archiving, traceability);
• interface with external vendors (central laboratory, data management, central pharmacy).

In large-scale projects or in structured DRCIs, the project manager may supervise several sponsor-side CRAs across a portfolio of studies — they may then also hold the title of coordinating CRA.

What this means in practice for the investigator: depending on the project phase, the point of contact is not the same. During the preparation and submission phase, it is the sponsor-side CRA (DRCI) who leads. During the conduct and recruitment phase, it is the investigator-side CRA who is in the department day to day. Confusing the two — or calling on one for the other's duties — is a frequent source of friction.

The 5 most frequent points of friction

1. The synopsis submitted too early

A scientifically incomplete synopsis submitted to the DRCI systematically generates a back-and-forth. The DRCI cannot assess the feasibility of a project whose design, endpoints, or sample size (NSN) are not defined. Ideally, before any submission to the DRCI, the synopsis must include at a minimum: primary objective, design, population, primary endpoint, and an estimate of the sample size (NSN).

If the investigator is not seasoned in this exercise, the members of the DRCI can support them, but their availability is often constrained and not always compatible with the schedules and expectations of investigators. This can therefore generate considerable friction.

2. Underestimating administrative timelines

The investigator often perceives the administrative phase as a formality. In reality, the DRCI must review the file internally (management, legal department, finance department), negotiate inter-establishment agreements in multicenter projects, identify and contract with vendors, and manage regulatory submissions in parallel. Each step has its own timelines, independent of the DRCI's will.

3. The undocumented budget

A budget that is not costed or that is built without the DRCI's fee schedules will be sent back. The budget must cover the real costs: dedicated CRA, per-visit hospital overcosts, additional examinations, sample logistics, sponsor insurance, data management. Underestimating the budget to improve the score in a call for projects is a risky strategy — funders detect unrealistic budgets.

4. The multicenter project without an established network

A project presented as multicenter without a letter of intent from the partner centers cannot be reviewed by the DRCI. Building the network of centers is the investigator's responsibility — the DRCI manages the agreements, not the scientific outreach.

5. Communication outside the channels

Contacting the CPP, the ANSM, or a partner center directly, or responding to a call for projects without going through the DRCI, creates documentary inconsistencies and administrative duplications. All official communications must go through the sponsor.

Good practices to streamline collaboration

Good practice	Concrete benefit
Initiate contact with the DRCI as early as the synopsis phase, before the complete protocol	Early identification of feasibility constraints and any budgetary blockers
Establish a provisional budget as of the first meeting between investigator and DRCI	Allows the DRCI to assess the workload and anticipate the necessary CRA resources
Designate a referent CRA from the start of the project	Continuity of the operational point of contact — a major factor of fluidity
Respect the document validation workflow before any submission, by defining who is responsible for it	Avoids inconsistencies between the submission file and the internal documents
Build administrative timelines into the synopsis's provisional schedule	A realistic schedule from submission — avoids late requests for extensions

In practice

The investigator ↔ DRCI friction is not inevitable — it almost always stems from a misreading of the roles and timeframes of each party. Mapping these responsibilities from the start of the project, and anticipating the administrative milestones on the same footing as the scientific ones, halves the back-and-forth and shortens the operational setup accordingly.